Johnson & Johnson stock trades 1.19 percent above Xetra close

Published on 10/20/2026 at 11:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter sales reached USD 25.40 billion, up 5.9 percent year over year. Johnson & Johnson stock costs EUR 227.43 against the EUR 224.75 Xetra close.

Results and dates shape valuation

Third-quarter sales reached USD 25.40 billion, up 5.9 percent year over year on October 13, 2026.
Bernstein raised its Johnson & Johnson target from USD 261 to USD 270 on October 15, 2026.
Johnson & Johnson stock traded at EUR 227.43 at 11:00 a.m. CEST on October 20, 2026, 1.19 percent above the EUR 224.75 Xetra close.
The company declared a USD 1.34 dividend, with November 24, 2026 as the ex-dividend date.

Flatlay mit Aktienzertifikat, ISIN-Karte, Stethoskop und Tabletten — Flatlay-Arrangement mit Aktienzertifikat und ISIN-Karte symbolisiert Aktie von Johnson & Johnson, ISIN US4781601046, im Pharmasektor, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) was trading at EUR 227.43 at Lang & Schwarz on October 20, 2026 at 11:00 a.m. CEST, 1.19 percent above the Xetra close of October 19, 2026 (EUR 224.75). On October 13, 2026, Johnson & Johnson reported third-quarter sales of USD 25.40 billion, up 5.9 percent from the year-earlier period.

Third-quarter sales set the tone

The result came with adjusted earnings per share of USD 2.59, while reported diluted earnings per share were USD 0.09 because of special charges linked to litigation and acquisitions. The company lifted its fiscal 2026 reported sales guidance midpoint to USD 101.20 billion from USD 101.10 billion, and its adjusted earnings-per-share midpoint to USD 11.10 from USD 11.04.

What does 2.5 percent MedTech growth mean?

MedTech sales rose 2.5 percent to USD 8.64 billion in the third quarter of 2026, compared with 7.9 percent operational growth in Innovative Medicine. Reuters reported on October 13, 2026, that international headwinds and the Middle East conflict weighed on the medical technology business, while Tremfya sales rose 68 percent to USD 2.40 billion.

Three milestones since October 2026

On October 13, 2026, Johnson & Johnson reported USD 25.40 billion in third-quarter sales. Also on October 13, 2026, the company declared a USD 1.34 quarterly dividend. On October 15, 2026, Investing.com reported that Bernstein raised its target from USD 261 to USD 270 while keeping a Market Perform rating. Bernstein also noted a fiscal 2027 earnings reset.

Next dates carry cash return

The next substantiated shareholder date is November 24, 2026, when the dividend goes ex-date and the shareholder register closes. The USD 1.34 payment is scheduled for December 8, 2026, according to Johnson & Johnson.

Stock holds above the Xetra close

The Lang & Schwarz quote puts the stock EUR 2.68 above the October 19, 2026 Xetra close. On the NYSE, it closed at USD 263.73 on October 19, 2026, according to Reuters.

Johnson & Johnson was trading at EUR 227.43 at Lang & Schwarz on October 20, 2026 at 11:00 a.m. CEST, 1.19 percent above the Xetra close of October 19, 2026 (EUR 224.75). The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.